CRSP (CRISPR Therapeutics AG) Marketable Securities: $2,018.48 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRSP CRISPR Therapeutics AG CRSP
31 GF Score
Price $46.73
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Marketable Securities?

CRISPR Therapeutics AG CRSP +0.41% 31 Marketable Securities is $2,018.48 Mil as of Mar. 2026. GuruFocus rates CRSP with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. CRISPR Therapeutics AG's Marketable Securities for the quarter that ended in Mar. 2026 was $2,018.48 Mil.

CRISPR Therapeutics AG's annual Marketable Securities increased from Dec. 2023 ($1,304.22 Mil) to Dec. 2024 ($1,605.57 Mil) and increased from Dec. 2024 ($1,605.57 Mil) to Dec. 2025 ($1,628.27 Mil).

CRISPR Therapeutics AG  (NAS:CRSP) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

CRISPR Therapeutics AG Marketable Securities Related Terms

CRISPR Therapeutics AG Marketable Securities Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Marketable Securities Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,456.10 1,603.43 1,304.22 1,605.57 1,628.27

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,620.10 1,527.62 1,629.21 1,628.27 2,018.48
CRSP
31GF Score
CRISPR Therapeutics AG CRSP
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $2,018.48 Mil mean?
CRISPR Therapeutics AG (CRSP) has a Marketable Securities of $2,018.48 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Marketable Securities too high?
CRISPR Therapeutics AG's current Marketable Securities is $2,018.48 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Marketable Securities compare to MANE and EWTX?
CRISPR Therapeutics AG's Marketable Securities of $2,018.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Marketable Securities is $2,018.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
CRISPR Therapeutics AG (CRSP) has a current Marketable Securities of $2,018.48 Mil. The current Marketable Securities is $2,018.48 Mil. CRISPR Therapeutics AG's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Marketable Securities is $2,018.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
31GF Score

Get the complete analysis for CRSP

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.73
Price